Alnylam Pharmaceuticals Inc (ALNY) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

234.56

USD

+4.06 (+1.76%)

AT CLOSE (AS OF Apr 17, 2025)

$30B

MARKET CAP

P/E Ratio

-2.18

EPS

$304

52 Week High

$142

52 Week Low

LIFE SCIENCES

Sector

ALNY Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$1.9B
Total Revenue	$2.2B
Cost Of Revenue	$323M
Costof Goods And Services Sold	$323M
Operating Income	-$177M
Selling General And Administrative	$976M
Research And Development	$1.1B
Operating Expenses	$2.1B
Investment Income Net	-
Net Interest Income	-$20M
Interest Income	$122M
Interest Expense	$142M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$57M
Income Before Tax	-$179M
Income Tax Expense	$99M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$278M
Comprehensive Income Net Of Tax	-
Ebit	-$236M
Ebitda	-$179M
Net Income	-$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$4.2B
Total Current Assets	$3.3B
Cash And Cash Equivalents At Carrying Value	$127M
Cash And Short Term Investments	$127M
Inventory	$79M
Current Net Receivables	-
Total Non Current Assets	$945M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	$1.7B
Other Current Assets	$117M
Other Non Current Assets	-
Total Liabilities	$4.2B
Total Current Liabilities	$1.2B
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$42M
Total Non Current Liabilities	$3B
Capital Lease Obligations	$271M
Long Term Debt	$1B
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$1.3B
Other Current Liabilities	$1B
Other Non Current Liabilities	$1.7B
Total Shareholder Equity	$67M
Treasury Stock	-
Retained Earnings	-$7.3B
Common Stock	$1.3M
Common Stock Shares Outstanding	$129M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$8.3M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$57M
Capital Expenditures	$34M
Change In Receivables	-
Change In Inventory	$14M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$294M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$278M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$1.9B
Total Revenue	$2.2B
Cost Of Revenue	$323M
Costof Goods And Services Sold	$323M
Operating Income	-$177M
Selling General And Administrative	$976M
Research And Development	$1.1B
Operating Expenses	$2.1B
Investment Income Net	-
Net Interest Income	-$20M
Interest Income	$122M
Interest Expense	$142M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$57M
Income Before Tax	-$179M
Income Tax Expense	$99M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$278M
Comprehensive Income Net Of Tax	-
Ebit	-$236M
Ebitda	-$179M
Net Income	-$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.00	9.68%	-	409,386,220
STSS	$0.03	20.75%	$522.68K	391,799,240
NVDA	$101.49	-2.87%	$2.48T	292,517,465
HTZ	$8.24	44.31%	$2.54B	266,908,117
FMTO	$0.02	-35.81%	$2.41M	198,396,141

Symbol	Price	Change %	Market Cap	Volume
LLY	$839.96	14.30%	$754.27B	10,853,385
PG	$170.63	2.55%	$400.10B	7,227,061
JNJ	$157.47	2.31%	$379.48B	10,981,067
ABBV	$172.99	0.76%	$306.02B	8,998,056
NVO	$58.08	-7.63%	$282.79B	32,220,629

Symbol	Price	Change %	Market Cap	Volume
MSGM	$2.75	145.54%	$8.75M	36,058,545
SXTC	$2.16	118.42%	$29.73M	51,508,885
ADGM	$1.78	92.81%	$54.65M	114,733,769
PNBK	$3.28	73.55%	$13.04M	1,511,087
RTC	$0.37	72.09%	$10.86M	187,018,434

Symbol	Price	Change %	Market Cap	Volume
JEWL	$0.00	-90.83%	$2.78M	470,134
LXEH	$6.84	-70.25%	$26.82M	1,373,607
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
MMV	$0.48	-51.02%	$11.90M	1,568,644

Quick Links

ALNY $234.56 (+1.76%) Quote details